Is the biosimilar dance party mandatory?
The Federal Circuit heard oral arguments this week in Amgen v Sandoz, and the dispute centres on a seemingly simple question that goes to a key part of the Biologics Price Competition and Innovation Act: what does “shall” mean?
Amgen v Sandoz involves Amgen’s biologic Neupogen and Sandoz’s biosimilar version Zarxio.
The Biologics Price Competition and Innovation Act (BPCIA) provides for an expedited pathway for Food and Drug Administration (FDA) approval of biosimilars - these applicants are often referred...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.